Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yannic Alber

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal of Cheminformatics|May 13, 2025
Generating diversity and securing completeness in algorithmic retrosynthesisFlorian Mrugalla, Christopher Franz, Yannic Alber, et al.
Biophysical Journal|April 27, 2019
Structure of a Therapeutic Full-Length Anti-NPRA IgG4 Antibody: Dissecting Conformational DiversityMichaela Blech, Stefan Hörer, Alexander B Kuhn, et al.
Science Translational Medicine|June 16, 2017
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumorsDennis Plenker, Maximilian Riedel, Johannes Brägelmann, et al.
Nature Communications|November 9, 2018
Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorsJana Fassunke, Fabienne Müller, Marina Keul, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal of Cheminformatics|May 13, 2025
Generating diversity and securing completeness in algorithmic retrosynthesisFlorian Mrugalla, Christopher Franz, Yannic Alber, et al.
Biophysical Journal|April 27, 2019
Structure of a Therapeutic Full-Length Anti-NPRA IgG4 Antibody: Dissecting Conformational DiversityMichaela Blech, Stefan Hörer, Alexander B Kuhn, et al.
Science Translational Medicine|June 16, 2017
Drugging the catalytically inactive state of RET kinase in RET-rearranged tumorsDennis Plenker, Maximilian Riedel, Johannes Brägelmann, et al.
Nature Communications|November 9, 2018
Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitorsJana Fassunke, Fabienne Müller, Marina Keul, et al.
Pageof 1